|
End-of-day quote
Oslo Bors
|
5-day change | 1st Jan Change | ||
| - PTS | -.--% |
|
-.--% | - |
| 08-28 | Nykode Therapeutics Raises NOK286 Million via Share Placement | MT |
| 08-27 | ABG Sundal Collier raises the target price for Nykode Therapeutics to 7.0 Norwegian kroner (4.5), reiterates buy | FW |
Company Valuation: VACY AS
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 23,372 | 8,287 | 6,988 | 994.7 | 787.6 | 1,275 | - | - |
| Change | - | -64.54% | -15.67% | -85.77% | -20.81% | 61.9% | - | - |
| Enterprise Value (EV) 1 | 21,490 | 6,164 | 5,327 | -251.9 | 236.2 | 791 | 646.7 | 762.8 |
| Change | - | -71.32% | -13.58% | -104.73% | 193.76% | 234.84% | -18.24% | 17.95% |
| P/E | -307x | -18.1x | -16.8x | -2.28x | -6.31x | -5.99x | 80.5x | -16.8x |
| PBR | - | 5.11x | 3.85x | 0.66x | 0.9x | 1.95x | 1.62x | 1.91x |
| PEG | - | -0x | 0.9x | -0.44x | 0.1x | -0.1x | -1x | 0x |
| Capitalization / Revenue | 74.5x | 88.8x | 49.5x | 9.75x | 182x | - | 6.07x | 16x |
| EV / Revenue | 68.5x | 66.1x | 37.8x | -2.47x | 54.6x | - | 3.08x | 9.59x |
| EV / EBITDA | -244x | -11.4x | -8.99x | 0.49x | -0.93x | -2.98x | -20.4x | -5.13x |
| EV / EBIT | -228x | -11.2x | -8.66x | 0.47x | -0.87x | -2.93x | -17.8x | -5.3x |
| EV / FCF | 8,641x | -25.5x | -5.11x | 0.44x | -0.84x | -5.53x | -170x | -5.67x |
| FCF Yield | 0.01% | -3.92% | -19.6% | 227% | -119% | -18.1% | -0.59% | -17.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.2627 | -1.55 | -1.271 | -1.336 | -0.382 | -0.6515 | 0.0485 | -0.233 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 313.5 | 93.31 | 141.1 | 102 | 4.326 | - | 209.9 | 79.53 |
| EBITDA 1 | -87.93 | -542.7 | -592.6 | -513.1 | -253.5 | -265.2 | -31.75 | -148.6 |
| EBIT 1 | -94.36 | -549.3 | -615.1 | -538.1 | -273 | -269.7 | -36.32 | -143.9 |
| Net income 1 | -82.32 | -441.7 | -372.3 | -432.2 | -116.9 | -209.5 | 9.966 | -88.42 |
| Net Debt 1 | -1,882 | -2,123 | -1,661 | -1,247 | -551.4 | -484.2 | -628.4 | -512.3 |
| Reference price 2 | 80.700 | 28.120 | 21.400 | 3.046 | 2.412 | 3.905 | 3.905 | 3.905 |
| Nbr of stocks (in thousands) | 289,619 | 294,694 | 326,546 | 326,546 | 326,546 | 326,546 | - | - |
| Announcement Date | 31/03/22 | 28/02/23 | 28/02/24 | 26/02/25 | 25/02/26 | - | - | - |
1NOK in Million2NOK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.09x | 7.5x | 15.07x | 1.41% | 71.94B | |
| 30.84x | 8.88x | 27.67x | 0.04% | 59.35B | |
| 31.46x | 6.7x | 17.4x | -.--% | 27.16B | |
| -74.58x | 14.32x | -78x | -.--% | 26.54B | |
| -15.32x | 5.85x | -7.35x | -.--% | 24.93B | |
| 28.35x | 5.34x | 17.75x | -.--% | 20.61B | |
| 43.56x | 15.96x | 32.38x | 0.35% | 15.03B | |
| 1013.62x | 35.48x | 612.89x | -.--% | 14.2B | |
| 17.9x | 5.33x | 12.45x | -.--% | 14.36B | |
| Average | 121.88x | 11.71x | 72.25x | 0.2% | 30.46B | |
| Weighted average by Cap. | 64.68x | 9.87x | 38.96x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- VACC Stock
- VACC Stock
- Valuation VACY AS
Select your edition
All financial news and data tailored to specific country editions
